IDYAIDEAYA Biosciences, Inc.
39.67USD+2.06%Mkt Cap: 3.83B $P/E: —3d ago
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral,…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precision oncology pipeline by initiating Part 2 monotherapy expansion for IDE892 and entering a clinical collaboration with Roche to explore combination regimens in MTAP‑deleted pancreatic cancer, an area with significant unmet medical need. With IDE892’s... | ||
IInsider Monkey | ||
MMT Newswires | ||